Escherichia coli Infections - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 152 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 30 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 15 molecules, respectively.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Escherichia coli Infections - Overview 8
Escherichia coli Infections - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 16
Products under Development by Universities/Institutes 19
Escherichia coli Infections - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Escherichia coli Infections - Companies Involved in Therapeutics Development 29
Abgentis Ltd 29
Adenium Biotech ApS 29
AstraZeneca Plc 30
Atterx Biotherapeutics Inc 30
AvidBiotics Corp 31
Cellceutix Corp 31
ContraFect Corp 32
Debiopharm International SA 32
Emergent BioSolutions Inc 33
F. Hoffmann-La Roche Ltd 33
GangaGen Inc 34
Hsiri Therapeutics LLC 34
ImmunoClin Corp 35
Immuron Ltd 35
Johnson & Johnson 36
Kyorin Pharmaceutical Co Ltd 36
Melinta Therapeutics Inc 37
Merck & Co Inc 37
Microbiotix Inc 38
Nabriva Therapeutics AG 38
Navigen Inc 39
Nosopharm SAS 39
Novabiotics Ltd 40
Paratek Pharmaceuticals Inc 40
Pherecydes Pharma SA 41
Phico Therapeutics Ltd 41
Recce Ltd 42
Sealife PHARMA GMBH 42
Soligenix Inc 43
Syntiron LLC 43
Tetraphase Pharmaceuticals Inc 44
Escherichia coli Infections - Drug Profiles 45
A-3APO - Drug Profile 45
AA-139 - Drug Profile 47
AM-8722 - Drug Profile 48
ASN-200 - Drug Profile 49
AvR2-V10 - Drug Profile 50
BC-7634 - Drug Profile 52
BC-9074 - Drug Profile 53
BC-9529 - Drug Profile 54
BC-9563 - Drug Profile 55
BIZ-20131 - Drug Profile 56
BIZ-20132 - Drug Profile 57
BIZ-20133 - Drug Profile 58
CA-824 - Drug Profile 59
CC-1807 - Drug Profile 60
CF-301 - Drug Profile 61
Debio-1454 - Drug Profile 65
dusquetide - Drug Profile 66
EBX-004 - Drug Profile 72
Escherichia coli (whole cell) vaccine - Drug Profile 73
Escherichia coli vaccine - Drug Profile 74
Escherichia coli vaccine - Drug Profile 75
ETEC [strain B7A] vaccine - Drug Profile 76
ETEC vaccine - Drug Profile 77
EV-035 - Drug Profile 78
GN-4474 - Drug Profile 80
GNeg Snare - Drug Profile 81
GYR-12 - Drug Profile 82
HT-07 - Drug Profile 83
infectious disease vaccine - Drug Profile 84
interleukin-22 - Drug Profile 85
JNJ-63871860 - Drug Profile 86
JSM-11 - Drug Profile 88
MBX-2319 - Drug Profile 89
MDN-0057 - Drug Profile 90
mirandamycin - Drug Profile 92
NBTI-5463 - Drug Profile 93
NOSO-95179 - Drug Profile 94
NP-432 - Drug Profile 95
omadacycline tosylate - Drug Profile 96
Onc-72 - Drug Profile 106
P-100031 - Drug Profile 107
Peptides for Infectious Diseases - Drug Profile 108
Polysaccharides for Bacterial Infections - Drug Profile 109
PP-0121 - Drug Profile 110
Proteins for Infectious Diseases - Drug Profile 112
PT-5 - Drug Profile 113
RECCE-327 - Drug Profile 114
Recombinant Protein for Escherichia Coli Infections - Drug Profile 116
RX-05 - Drug Profile 117
RXP-873 - Drug Profile 118
SE-1 - Drug Profile 119
Shigetec - Drug Profile 120
SLP-0901 - Drug Profile 121
SLP-0905 - Drug Profile 122
Small Molecule for Malaria and Bacterial Infections - Drug Profile 123
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 124
Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 125
Small Molecules for Escherichia coli Infections - Drug Profile 126
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 127
Small Molecules to Inhibit DbpA for Escherichia coli Infections - Drug Profile 128
Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 129
SPR-741 - Drug Profile 130
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 133
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 134
Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 135
Synthetic Peptides for Escherichia Coli Infections - Drug Profile 136
Synthetic Peptides for Infectious Disease - Drug Profile 137
TN-5 - Drug Profile 138
TP-6076 - Drug Profile 139
Escherichia coli Infections - Dormant Projects 140
Escherichia coli Infections - Discontinued Products 143
Escherichia coli Infections - Product Development Milestones 144
Featured News & Press Releases 144
Appendix 147
Methodology 147
Coverage 147
Secondary Research 147
Primary Research 147
Expert Panel Validation 147
Contact Us 147
Disclaimer 148

List of Tables

Number of Products under Development for Escherichia coli Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Escherichia coli Infections - Pipeline by Abgentis Ltd, H1 2017
Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H1 2017
Escherichia coli Infections - Pipeline by AstraZeneca Plc, H1 2017
Escherichia coli Infections - Pipeline by Atterx Biotherapeutics Inc, H1 2017
Escherichia coli Infections - Pipeline by AvidBiotics Corp, H1 2017
Escherichia coli Infections - Pipeline by Cellceutix Corp, H1 2017
Escherichia coli Infections - Pipeline by ContraFect Corp, H1 2017
Escherichia coli Infections - Pipeline by Debiopharm International SA, H1 2017
Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Escherichia coli Infections - Pipeline by GangaGen Inc, H1 2017
Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H1 2017
Escherichia coli Infections - Pipeline by ImmunoClin Corp, H1 2017
Escherichia coli Infections - Pipeline by Immuron Ltd, H1 2017
Escherichia coli Infections - Pipeline by Johnson & Johnson, H1 2017
Escherichia coli Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
Escherichia coli Infections - Pipeline by Merck & Co Inc, H1 2017
Escherichia coli Infections - Pipeline by Microbiotix Inc, H1 2017
Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H1 2017
Escherichia coli Infections - Pipeline by Navigen Inc, H1 2017
Escherichia coli Infections - Pipeline by Nosopharm SAS, H1 2017
Escherichia coli Infections - Pipeline by Novabiotics Ltd, H1 2017
Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H1 2017
Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H1 2017
Escherichia coli Infections - Pipeline by Recce Ltd, H1 2017
Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H1 2017
Escherichia coli Infections - Pipeline by Soligenix Inc, H1 2017
Escherichia coli Infections - Pipeline by Syntiron LLC, H1 2017
Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Escherichia coli Infections - Dormant Projects, H1 2017
Escherichia coli Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017
Escherichia coli Infections - Dormant Projects, H1 2017 (Contd..2), H1 2017
Escherichia coli Infections - Discontinued Products, H1 2017